Eisai enters Canadian pharmaceutical market

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

“Eisai's entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region”

"Eisai's entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region," said Hajime Shimizu, Chairman and CEO, Eisai Inc. "Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide."

Eisai Limited is working with Health Canada on the approval of select products from the Eisai Inc. portfolio to be introduced in the Canadian market. Over time, additional medicines from Eisai's portfolio of currently marketed products may be introduced to the Canadian market as well as future products from Eisai's pipeline. The company's areas of commercial focus will include neurology, gastrointestinal disorders and oncology/critical care.

SOURCE Eisai Inc.